The practical way to compare an original premarket approval application and its supplement records is to treat the supplement not as a replacement file but as a scoped change request attached to a baseline. A PMA supplement is the submission required for a change affecting the safety or effectiveness of an approved device [1]. The original PMA supplies the approved indication, design description, manufacturing methods, and the full clinical and nonclinical evidence package. A supplement then describes a specific alteration, explains the reason for it, and carries only the testing necessary to support that alteration [8]. The comparison therefore has three layers: identify the exact change, determine what data the supplement adds or references, and assess whether the remaining original PMA evidence still applies to the changed device. This article outlines a decision workflow for that comparison and shows how the public record constrains what an analyst can substantiate.

Start With the Regulatory Event Type Before Comparing Content

Not every postapproval change belongs in the same evidentiary category. FDA describes panel-track supplements, 180-day supplements, 135-day supplements, 30-day notices, site change supplements, and periodic reporting paths, each triggered by the nature of the change and the data required to support it [1]. A panel-track supplement is used for a significant design or performance change or a new indication and generally requires substantial clinical data and a full PMA review, possibly including an advisory panel [1]. A manufacturing site change, by contrast, may be a 180-day supplement when the site was not approved in the original PMA or a prior supplement and the change affects safety or effectiveness [1].

The comparison should therefore begin by recording the supplement type declared by the applicant. The cover letter is expected to identify whether the submission is an original PMA, a PMA supplement, or another filing [2]. That classification tells the reviewer what rigor to expect. A panel-track supplement should contain evidence comparable in weight to an original application for the affected question, while a site change supplement may rely on quality system and sterilization validation rather than new clinical outcome data. Comparing an original PMA to a limited manufacturing supplement on clinical grounds alone would misread the intended scope of the filing.

Map the Technical Delta Against the Original Baseline

A usable comparison depends on isolating what changed. The original PMA requires a complete description of the device, its functional components, relevant properties, principles of operation, and manufacturing methods in enough detail for a knowledgeable person to judge quality control [7]. A supplement must summarize the change being requested and explain the reason for each change [8]. The analyst should create a two-column map: original specification or method in one column, revised text or process in the other, with the supplement's stated reason beside it. This makes the comparison auditable rather than impressionistic.

The same discipline applies to evidence. An original PMA contains nonclinical laboratory studies, engineering data, and clinical investigations described by subject selection, endpoints, adverse reactions, device failures, and statistical analyses [5]. A supplement may reference previously submitted information or include only the new test reports needed for the modification [8]. When comparing records, mark each original study as still applicable, superseded, or of unclear relevance to the changed device. That status—not the presence of a document—is the substantive finding. FDA's own filing checklists require reviewers to note whether nonclinical data appears in the current submission or is referenced from another submission [4].

Worked Example: A Sterilization Site Change

Suppose an original PMA approved a sterile implant made at one facility with a named sterilization method. A later supplement requests use of a different manufacturing or packaging facility. Under FDA's description, a site change requires a 180-day supplement when the site was not approved in the original PMA or a prior supplement and the change affects the finished device's safety or effectiveness [1]. The analyst would compare the original record's facility description and sterilization validation with the supplement's new site information.

The substantive questions are whether the new site uses identical or modified sterilization procedures, whether packaging changed, and whether the supplement supplies new validation data or references the original testing. If the public record only shows that a site change supplement was approved, the analyst can state the approval event but not the technical equivalence of the new operation. A complete comparison would require the nonpublic validation reports. The example shows why the comparison result should be phrased as an evidence-status finding rather than a conclusion that the changed device shares the original PMA's full supporting data.

Read the Public Record as a Partial Artifact

The publicly available PMA database and the Summary of Safety and Effectiveness Data are the main external records, but they do not expose the full application. FDA prepares the SSED because the statute requires a detailed summary of the safety and effectiveness data on which the approval or denial decision is based; the applicant does not submit it [2]. That means original PMA and supplement comparisons often rely on a distilled agency document rather than the underlying study reports. An analyst can confirm an approval event and broad condition, but cannot compare line-level manufacturing procedures or clinical datasets from the public summary alone.

This limit changes what counts as a valid conclusion. It is defensible to state that an original PMA and a panel-track supplement were both reviewed against safety and effectiveness questions, or that a site change supplement addressed a previously unapproved facility. It is not defensible to infer that a later device is clinically equivalent to the earlier version merely because both records sit under the same PMA number. The supplement regulation permits changes without a supplement only when they do not affect safety or effectiveness and are reported in periodic reports, or when they follow an approved predetermined change control plan [8]. Public records may not say which route a particular alteration took; the analyst should note that gap explicitly.

A Suggested Workflow for a Device-Level Evaluation

The following sequence is a suggested editorial framework, not an FDA procedure. First, pull the original PMA record and list the approved indication, device description, manufacturing sites, sterilization method, and any panel review history. Second, retrieve every supplement record associated with that PMA number and classify each by the change type listed in the regulation: indication, labeling, facility, sterilization, packaging, design or performance, or expiration dating [8]. Third, for each supplement, identify from the available record which change it addressed and whether the filing references prior data or reports new testing.

Fourth, produce a cumulative change map. A device that received only labeling and packaging supplements has a narrow technical delta, while one with repeated design, component, or site supplements has a materially different approved configuration. Finally, flag evidence gaps where the public record does not show whether original validation still covers the current device. This workflow avoids treating the supplement stack as one undifferentiated category and makes the comparison repeatable for regulatory affairs teams preparing a change assessment or external analysts reviewing approval history.